Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023
31 Luglio 2023 - 10:05PM
Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage
biopharmaceutical company focused on developing medicines to target
diseases driven by abnormally elevated aldosterone, today announced
it will report its financial results from the second quarter ended
June 30, 2023, after the financial markets close on Monday, August
7, 2023.
Monday, August 7th @
4:30 p.m. ET |
|
Domestic: |
1-877-704-4453 |
International: |
1-201-389-0920 |
Conference ID: |
13739672 |
Webcast: |
Link |
|
|
If you would like a call back, please click this
link, which will be made active 15 minutes prior to the scheduled
start time. A live webcast of the conference call may be found
here. A replay of the call will be available on the “News &
Events” page in the Investor Relations section of the Mineralys
Therapeutics website.
About MineralysMineralys Therapeutics is a
clinical-stage biopharmaceutical company focused on developing
medicines to target diseases driven by abnormally elevated
aldosterone. Its initial product candidate, lorundrostat, is a
proprietary, orally administered, highly selective aldosterone
synthase inhibitor that Mineralys Therapeutics is developing for
cardiorenal conditions affected by abnormally elevated aldosterone,
including hypertension and chronic kidney disease. Mineralys is
based in Radnor, Pennsylvania, and was founded by Catalys Pacific.
For more information, please visit https://mineralystx.com. Follow
Mineralys on LinkedIn.
Contact:Investor
Relationsinvestorrelations@mineralystx.com
Media RelationsTom WeibleElixir
Health Public RelationsPhone: (1) 515-707-9678Email:
tweible@elixirhealthpr.com
Grafico Azioni Mineralys Therapeutics (NASDAQ:MLYS)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Mineralys Therapeutics (NASDAQ:MLYS)
Storico
Da Lug 2023 a Lug 2024